Analyst Price Targets — CNTB
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 9, 2026 11:57 am | — | Oppenheimer | $8.00 | $2.57 | TheFly | Connect Biopharma initiated with an Outperform at Oppenheimer |
| June 26, 2026 9:55 am | — | Piper Sandler | $7.00 | $2.07 | TheFly | Connect Biopharma initiated with an Overweight at Piper Sandler |
| June 18, 2026 10:49 am | Brandon Folkes | H.C. Wainwright | $7.00 | $2.08 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Connect Biopharma Holdings Ltd (CNTB) |
| May 26, 2026 9:23 am | Edward Nash | Canaccord Genuity | $6.00 | $2.35 | TheFly | Connect Biopharma initiated with a Buy at Canaccord |
| May 21, 2026 10:06 am | Olivia Brayer | Cantor Fitzgerald | $4.00 | $2.31 | TheFly | Connect Biopharma initiated with an Overweight at Cantor Fitzgerald |
| December 1, 2025 1:40 pm | Thomas Flaten | Lake Street | $9.00 | $2.86 | TheFly | Connect Biopharma initiated with a Buy at Lake Street |
| May 5, 2022 4:40 am | Joseph Catanzaro | Piper Sandler | $1.50 | $0.82 | TheFly | Connect Biopharma downgraded to Neutral from Overweight at Piper Sandler |
Latest News for CNTB
– On track to also complete enrollment in the Seabreeze STAT COPD study this month – – Expect to report topline data from Seabreeze STAT Asthma study in early September 2026 – – Strong balance sheet with cash runway into 2H 2027 – SAN DIEGO, June 17, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company…
Connect Biopharma NASDAQ: CNTB Chief Executive Officer Barry Quart said the company's rademikibart program continues to show a differentiated clinical and mechanistic profile as the company awaits mid-2026 data from its SEABREEZE study.
SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that Company management will participate in a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference on Tuesday, May 19,…
– Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD continuing as planned based on independent DMC review of pre-specified interim analysis –
Connect Biopharma Holdings is rated a risky Buy, with high upside potential hinging on mid-2026 Phase 2 trial results for rademikibart. Rademikibart has shown superior efficacy and safety to Dupixent in China Phase 3 trials, with commercialization led by Simcere and low-double-digit royalties to CNTB. CNTB is targeting the emergency asthma and COPD settings in the US, a market with no approved biologics, and expects…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CNTB.
U.S. House Trading
No House trades found for CNTB.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.